Long-term outcomes of transplant kidneys donated after circulatory death.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
25 05 2022
Historique:
received: 30 08 2021
pubmed: 18 12 2021
medline: 27 5 2022
entrez: 17 12 2021
Statut: ppublish

Résumé

Donation after circulatory death (DCD) represents up to 40% of used kidney grafts. While studies have shown similar outcomes compared with donation after brain death (DBD) in the short term and mid-term, no data on long-term outcomes exist. We retrospectively analysed patients transplanted at our institution between January 1985 and March 2000. All DCD recipients were matched one-to-one with patients transplanted with DBD grafts during this period according to sex, age and year of transplantation and followed up until December 2020. During this period, 1133 kidney transplantations were performed, of which 122 were with a DCD graft. The median graft survival after 35 years of follow-up was 23 years [277 months {95% confidence interval (CI) 182-372}] in DBD recipients and 24.5 years [289 months (95% CI 245-333)] in DCD recipients (P = 0.65; hazard ratio 0.91). Delayed graft function occurred in 47 patients in the DCD group compared with 23 in the DBD group (P < 0.001), albeit without a significant long-term outcome difference in graft or patient survival. We could not show any difference in graft function in terms of creatinine levels (133 versus 119 µmol/L), proteinuria (370 versus 240 mg/24 h) and glomerular filtration rate slope (-0.6 versus -0.3 mL/min/year) between the two groups for graft survival >20 years. This is the first study to show similar graft survival and function in DCD kidneys compared with DBD kidneys after 35 years of follow-up. DCD grafts are a valuable resource and can be utilized in the same way as DBD grafts.

Sections du résumé

BACKGROUND
Donation after circulatory death (DCD) represents up to 40% of used kidney grafts. While studies have shown similar outcomes compared with donation after brain death (DBD) in the short term and mid-term, no data on long-term outcomes exist.
METHODS
We retrospectively analysed patients transplanted at our institution between January 1985 and March 2000. All DCD recipients were matched one-to-one with patients transplanted with DBD grafts during this period according to sex, age and year of transplantation and followed up until December 2020. During this period, 1133 kidney transplantations were performed, of which 122 were with a DCD graft.
RESULTS
The median graft survival after 35 years of follow-up was 23 years [277 months {95% confidence interval (CI) 182-372}] in DBD recipients and 24.5 years [289 months (95% CI 245-333)] in DCD recipients (P = 0.65; hazard ratio 0.91). Delayed graft function occurred in 47 patients in the DCD group compared with 23 in the DBD group (P < 0.001), albeit without a significant long-term outcome difference in graft or patient survival. We could not show any difference in graft function in terms of creatinine levels (133 versus 119 µmol/L), proteinuria (370 versus 240 mg/24 h) and glomerular filtration rate slope (-0.6 versus -0.3 mL/min/year) between the two groups for graft survival >20 years.
CONCLUSIONS
This is the first study to show similar graft survival and function in DCD kidneys compared with DBD kidneys after 35 years of follow-up. DCD grafts are a valuable resource and can be utilized in the same way as DBD grafts.

Identifiants

pubmed: 34919732
pii: 6468756
doi: 10.1093/ndt/gfab358
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1181-1187

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Auteurs

Amélie K Müller (AK)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Eva Breuer (E)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Kerstin Hübel (K)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.
Department of Nephrology, University Hospital of Zürich, Zürich, Switzerland.

Kuno Lehmann (K)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Pietro Cippà (P)

Department of Nephrology, Ospedale Regionale di Lugano, Lugano, Switzerland.

Thomas Schachtner (T)

Department of Nephrology, University Hospital of Zürich, Zürich, Switzerland.

Christian Oberkofler (C)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Thomas Müller (T)

Department of Nephrology, University Hospital of Zürich, Zürich, Switzerland.

Markus Weber (M)

Department of Surgery, Stadtspital Triemli, Zürich, Switzerland.

Philipp Dutkowski (P)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Pierre-Alain Clavien (PA)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Olivier de Rougemont (O)

Department of Surgery and Transplantation, University Hospital of Zürich, Zürich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH